209459-11-0

Basic information

• Product Name: 7-Benzothiazolecarboxylicacid,2-amino-,methylester
• Synonyms: 7-Benzothiazolecarboxylicacid,2-amino-,methylester;7-Benzothiazolecarboxylicacid,2-amino-,methylester(9CI);Methyl 2-aMinobenzo[d]thiazole-7-carboxylate;Methyl 2-aMino-1,3-benzothiazole-7-carboxylate;2-AMino-benzothiazole-7-carboxylic acid Methyl ester;2-amino-7-Benzothiazolecarboxylic acid methyl ester
• CAS NO: 209459-11-0
• Molecular Formula: C₉H₈N₂O₂S
• Molecular Weight: 208.23702
• Product Categories: AMINOACID;BENZOTHIAZOLE
• Mol File: 209459-11-0.mol

Chemical Properties

• Boiling Point: 378.379°C at 760 mmHg
• Flash Point: 182.638°C
• Appearance: /
• Density: 1.422g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.7
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.26±0.30(Predicted)
• CAS DataBase Reference: 7-Benzothiazolecarboxylicacid,2-amino-,methylester(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Benzothiazolecarboxylicacid,2-amino-,methylester(209459-11-0)
• EPA Substance Registry System: 7-Benzothiazolecarboxylicacid,2-amino-,methylester(209459-11-0)

Safety Data

• Hazardous Substances Data: 209459-11-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Benzothiazolecarboxylic acid, 2-amino, methyl ester is used as a reactant for the creation of spirocyclic hydantoin antagonists of LFA-1 (Lymphocyte Function-Associated Antigen-1). LFA-1 is a cell adhesion molecule involved in various immune responses, and its antagonists have potential applications in treating autoimmune diseases, inflammatory disorders, and transplant rejection.
The synthesis of spirocyclic hydantoin antagonists involves the use of 7-Benzothiazolecarboxylic acid, 2-amino, methyl ester as a key intermediate. The molecule's unique structure allows for the formation of spirocyclic hydantoins, which can modulate the activity of LFA-1 and potentially provide therapeutic benefits in the treatment of various diseases.

InChI:InChI=1/C9H8N2O2S/c1-13-8(12)5-3-2-4-6-7(5)14-9(10)11-6/h2-4H,1H3,(H2,10,11)

Upstream product

• 1038509-28-2 methyl benzo[d]thiazole-7-carboxylate 
• 3425-46-5 potassium selenocyanate 
• 4518-10-9 Methyl 3-aminobenzoate 
• 192948-00-8 methyl 3-thioureidobenzoate 

Downstream Products

• 1038509-28-2 methyl benzo[d]thiazole-7-carboxylate 
• 123158-77-0 2-amino-5-methyl-3-nitrophenyliodide 
• 677304-83-5 benzo[d]thiazole-7-carboxylic acid 
• 124371-49-9 benzothiadiazole-7-carboxylic acid chloride 
• 35272-27-6 benzo[d][1,2,3]thiadiazole-7-carboxylic acid 

Relevant articles and documents

Iodine-catalyzed amination of benzothiazoles with KSeCN in water to access primary 2-aminobenzothiazoles

A facile and sustainable approach for the amination of benzothiazoles with KSeCN using iodine as the catalyst in water has been disclosed under transition-metal free conditions. The reaction proceeded smoothly to afford various primary 2-amino benzothiazoles in up to 96% yield. A series of control experiments were performed, suggesting a ring-opening mechanism was involved via a radical process. This protocol provides efficient synthesis of primary 2-aminobenzothiazoles

2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES

The invention relates to novel 2-aza-bicyclo[2.2.1]heptane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as m

TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel trans-3-aza-bicyclo[3.1.0]hexane derivatives of formula (I), wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES

The invention relates to novel 2-aza-bicyclo[3.1.0]hexane derivatives of Formula (I) wherein A, B, n and R1 are as described in the description, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.